Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosis

Cell Cycle

Volumn 4, Issue 3, 2005, Pages 465-472

  Gallagher, Stuart ^a   Kefford, Richard F ^a   Rizos, Helen ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Apoptosis; Melanoma; p14ARF; p53

Indexed keywords

ADENOVIRUS VECTOR; DOXORUBICIN; GYRASE INHIBITOR; PROTEIN P14ARF; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CELL TYPE; CYTOTOXICITY; FIBROBLAST; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIZATION; TUMOR CELL LINE;

EID: 25144503764     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.3.1526     Document Type: Article

References (67)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-7.
2. Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003; 15:157-61.
3. Soufir N, Avril M-F, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, The French Familial Melanoma Group, Bénard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998; 7:209-16.
4. INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: Effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999; 25:339-48.
5. INK4 gene in Australian melanoma kindreds. Hum Mol Gen 1995; 4:1845-52.
6. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: Nonrandom distribution of base substitutions. Genes Chromosomes Cancer 1996; 15:77-88.
7. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jiménez L, Milà M, Kefford RF. A melanoma-associated germline mutation in exon 1β inactivates p14ARF. Oncogene 2001; 20:5543-7.
8. ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001; 10:55-62.
9. Hewitt C, Wu CL, Evan G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002; 11:1273-9.
10. Freedberg DE, Mistry S, Russak J, Gai W, Kaplow M, Osman I, Turner F, Houghton A, Busam KJ, Bishop T, Bastian BC, Newton Bishop JA, Polsky D. Genetic and epigenetic alterations of p14ARF are frequent in human melanoma metastases. Phoenix, Arizona, USA: Second Melanoma Research Congress, 2004.
11. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725-34.
12. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92:713-23.
13. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and mdm2. Proc Natl Acad Sci USA 1998; 95:8292-7.
14. ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-14.
15. ARF links the tumour suppressor p53 to Ras. Nature 1998; 395:125-6.
16. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 1998; 12:2424-33.
17. Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH. p14ARF links the tumour suppressors RB and p53. Nature 1998; 395:124-5.
18. Sherr CJ. An Arf(GFP/GFP) reporter mouse reveals that the Arf tumor suppressor monitors latent oncogenic signals in vivo. Cell Cycle 2004; 3:239-40.
19. Khan SH, Moritsugu J, Wahl GM. Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proc Natl Acad Sci USA 2000; 97:3266-71.
20. Khan S, Guevara C, Fujii G, Parry D. p14ARF is a component of the p53 response following ionizing radiation of normal human fibroblasts. Oncogene 2004; 23:6040-6.
21. Weber HO, Samuel T, Rauch P, Funk JO. Human p14ARF-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002; 21:3207-12.
22. INK4a and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000; 2:148-55.
23. Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP. p53-independent functions of the p19ARF tumor suppressor. Genes Dev 2000; 14:2358-65.
24. Esteller M, et al. Hypermethylation-associated inactivation of p14ARF is independent of p16INK4a methylation and p53 mutational status. Cancer Res 2000; 60:129-33.
25. Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, Sidransky D. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in nonsmall cell lung cancer. Oncogene 1999; 18:5843-9.
26. Yarbrough WG, Bessho M, Zanation A, Bisi JE, Xiong Y. Human tumour suppressor ARF impedes S-phase progression independent of p53. Cancer Res 2002; 62:1171-7.
27. Eymin B, Karayan L, Séité P, Brambilla C, Brambilla E, Larson C-J, Gazzéri S. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20:1033-41.
28. 2 cell cycle arrest in p53 and p21 deficient cells by downregulating p34cdc2 kinase activity. J Biol Chem 2004; 6:6.
29. Sugimoto M, Kuo M-L, Roussel MF, Sherr CJ. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. Mol Cell 2003; 11:415-24.
30. Mason SL, Loughran O, La Thangue NB. p14ARF regulates E2F activity. Oncogene 2002; 21:4220-30.
31. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1 and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002; 22:8398-408.
32. Vivo M, Calogero RA, Sansone F, Calabrò V, Parisi T, Borrelli L, Saviozzi S, La Mantia G. The human tumor suppressor ARF interacts with spinophilin/neurabin II, a type 1 protein-phosphatase-binding protein. J Biol Chem 2001; 276:14161-9.
33. Karayan L, Riou J-F, Séité P, Migeon J, Cantereau A, Larson C-J. Human ARF protein interacts with Topoisomerase I and stimulates its activity. Oncogene 2001; 20:836-48.
34. 1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Mol Cancer Res 2003; 1:195-206.
35. Jackson MW, Lindström MS, Berberich SJ. MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation. Oncogene 2001; 276:25336-41.
36. ARF tumour suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor 1a (HIF-1a) and inihibits HIF-1 mediated transcription. J Biol Chem 2001; 276:28421-9.
37. Sugihara T, Kaul SC, Kato J, Reddel RR, Nomura H, Wadhwa R. Pex19p dampens the p19ARF-p53-p21WAF1 tumor suppressor pathway. J Biol Chem 2001; 276:18649-52.
38. ARF) in activating p53. J Biol Chem 2002; 277:37765-70.
39. E4F transcriptional repressor enhances cell cycle inhibition. J Biol Chem 2003; 278:4981-9.
40. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. Tumor Suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12:1151-61.
41. Woods YL, Xirodimas DP, Prescott AR, Sparks A, Lane DP, Saville MK. p14Arf promotes SUMO conjugation of Werners helicase. J Biol Chem 2004; 279:50157-66.
42. Martelli F, Hamilton T, Silver DP, Sharpless NE, Bardeesy N, Rokas M, DePinho RA, Livingston DM, Grossman SR. p19ARF targets certain E2F species for degradation. Proc Natl Acad Sci USA 2001; 98:4455-60.
43. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83:993-1000.
44. ARF tumor suppressor. Genes Dev 1998; 12:2434-42.
45. Russell JL, Poers JT, Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG. ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol Cell Biol 2002; 22:1360-1368.
46. Tsuji K, Mizumoto K, Sudo H, Kouyama K, Ogata E, Matsuoka M. p53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochem Biophys Res Commun 2002; 295:621-9.
47. ARF tumor suppressor are involved in p53-independent apoptosis. Biochem Biophys Res Commun 2003; 301:1000-10.
48. Drayton S, Rowe J, Jones R, Vatcheva R, Cuthbert-Heavens D, Marshall J, Fried M, Peters G. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell 2003; 4:301-10.
49. 2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22:1822-35.
50. Deng Q, Kim H, Vandier D, Jung Y, Rikiyama T, Sgagias MK, Goldsmith M, Cowan KH. Recombinant adenovirus-mediated p14ARF overexpression sensitizes human breast cancer cells to cisplatin. Biocem Biophys Res Commun 2002; 296:792-8.
51. Yang CT, You L, Yeh, CC, Chang JW, Zhang F, McCormick F, Jablons DM. Adenovirus-mediated p14ARF gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92:636-41.
52. Kim M, Sgagias M, Deng X, Jung YJ, Rikiyama T, Lee K, Ouellette M, Cowan K. Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression. Biochem Biophys Res Commun 2004; 320:138-44.
53. Hemmati PG, Gillissen B, von Haefen C, Wendt J, Starck L, Güner D, Dorken B, Daniel PT. Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis. Oncogene 2002; 21:3149-3161.
54. INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res 1999; 9:10-9.
55. Brookes S, Rowe J, Ruas M, Llanos S, Clark PA, Lomax M, James MC, Vatcheva R, Bates S, Vousden KH, Parry D, Gruis N, Smit N, Bergman W, Peters G. INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J 2002; 21:2936-45.
56. Sandoval R, Xue J, Pilkinton M, Salvi D, Kiyokawa H, Colamonici OR. Different requirements for the cytostatic and apoptotic effects of type I IFNs: Induction of apoptosis requires ARF, but not p53 in osteosarcoma cell lines. J Biol Chem 2004; 279:32275-80.
57. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8:307-18.
58. Saito S, Goodarzi AA, Higashimoto Y, Noda Y, Lees-Miller SP, Appella E, Anderson CW. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 2002; 277:12491-4.
59. Blagosklonny MV, Demidenko ZN, Fojo T. Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrity. Cell Cycle 2002; 1:67-74.
60. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001; 20:147-55.
61. Paquet C, Schmitt E, Beauchemin M, Bertrand R. Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells. Apoptosis 2004; 9:815-31.
62. 2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Ther 1999; 6:1054-63.
63. Berkovich E, Lamed Y, Ginsberg D. E2F and Ras synergize in transcriptionally activating p14ARF expression. Cell Cycle 2003; 2:127-33.
64. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19-20.
65. Groth A, Weber JD, Willumsen BM, Sherr CJ, Roussel MF. Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases. J Biol Chem 2000; 275:27473-80.
66. Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12:3008-19.
67. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, Frattini M, Pilotti S, Anichini A, Tragni G, Parmiani G, Pierotti MA, Rodolfo M. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 2004; 23:5968-77.